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Abstract 
Objective: Urolithin A (UroA) is a major metabolite of ellagic acid produced following microbial ca-
tabolism in the gut. Emerging evidence has suggested that UroA modulates energy metabolism in 
various cells. However, UroA’s physiological functions related to obesity and insulin resistance re-
main unclear. Methods: Male mice were intraperitoneally administrated either UroA or dimethyl sul-
foxide (vehicle) along with a high-fat diet for 12 weeks. Insulin sensitivity was evaluated via glucose 
and insulin tolerance tests and acute insulin signaling. The effects of UroA on hepatic triglyceride 
accumulation, adipocyte size, mitochondrial DNA content, and proinflammatory gene expressions 
were determined. The impact of UroA on macrophage polarization and mitochondrial respiration 
were assessed in bone marrow–derived macrophages. Results: Administration of UroA (1) improved 
systemic insulin sensitivity, (2) attenuated triglyceride accumulation and elevated mitochondrial 
biogenesis in the liver, (3) reduced adipocyte hypertrophy and macrophage infiltration into the adi-
pose tissue, and (4) altered M1/M2 polarization in peritoneal macrophages. In addition, UroA fa-
vored macrophage M2 polarization and mitochondrial respiration in bone marrow–derived macro-
phages. Conclusions: UroA plays a direct role in improving systemic insulin sensitivity independent 
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of its parental compounds. This work supports UroA’s role in the metabolic benefits of ellagic acid–
rich foods and highlights the significance of its microbial transformation in the gut. 
 
Introduction 
 
The gut microbiota play a crucial role in host metabolism by enhancing energy extraction, 
generating signaling molecules such as short chain fatty acids, and modulating immune 
function (1). Moreover, gut microbes are involved in numerous catabolic pathways that 
can either intensify or annul the biological functions of dietary bioactive molecules. For 
example, gut microbial metabolism of dietary polyphenols could explain how these com-
pounds exert an array of health benefits against obesity and its associated metabolic com-
plications (2). Unfortunately, most polyphenolic compounds are notorious for their low 
bioavailability (3). A better understanding of how microbial catabolism in the gut gener-
ates bioavailable metabolites may one day aid in increasing the systemic levels of these 
compounds to mediate beneficial metabolic effects. 
Urolithins (Uro) are one of the most extensively studied gut metabolites generated from 
ellagitannins (ET) and the free form of ellagic acid (EA). Uro possess a common 6H-
dibenzo[b,d]-pyran-6-one nucleus and decreasing number of phenolic hydroxyl groups 
(UroD → UroC → UroA → UroB) following a series of microbial enzymatic actions in the 
gut (4) (Figure 1A). On intestinal absorption, Uro were shown to undergo phase II bio-
transformation in the liver, resulting in conjugated UroA metabolites, such as UroA-
glucuronide and UroA-aglycone to a lesser amount (5). A recent study by Sandhu et al. 
demonstrated concentrations of UroA-glucuronide in human plasma around 0.142 μM to 
5.96 μM 2 hours after chronic consumption of strawberry drink (6). In an extensive review, 
Tomás-Barberan et al. cited several studies reporting that UroA-glucuronide can be found 
at concentrations ranging from 0.024 μM to 35 μM in human plasma (7). However, these 
concentrations were shown to be highly dependent on the gut microbial composition of 
the host (8). 
Despite numerous studies on pharmacokinetic production of UroA in the gut and its 
biological fate determination (7), less information is available on the physiological func-
tions of Uro or the bioactive conjugates. Cerda et al. first proposed the hypothesis that Uro 
drive the health effects of ET and EA-containing foods (9). Afterward, a growing body of 
evidence has indicated that Uro convey metabolic benefits of EA-rich foods (10). In pio-
neering these efforts, Larrosa et al. reported that dietary administration of synthetic UroA 
(15 mg/kg of body weight (BW)/d) was effective in attenuating the colonic inflammation 
in a rat model, identifying the UroA could be a key anti-inflammatory metabolite derived 
from pomegranate extract (11). This anti-inflammatory role of UroA was confirmed in hu-
man colonic fibroblasts (12). Notably, the biological activities of UroA are found in various 
cell types beyond the site of UroA production and absorption in colorectal cells. Several in 
vitro studies have demonstrated the anti-inflammatory and antioxidative characteristics of 
UroA in immune, endothelial, and aortic cells (13–16). We demonstrated that UroA atten-
uated triglyceride (TG) accumulation in the primary human adipocytes (17). Recently, Ryu 
et al. demonstrated that UroA exhibited the unique function in promoting autophagic flux, 
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which led to increased longevity in Caenorhabditis elegans (18). Additionally, several studies 
demonstrated cardioprotective roles for UroA (19,20). 
The aforementioned studies led us to hypothesize that UroA exerts the systemic meta-
bolic benefits independent of its parental compounds EA or ET. To investigate the direct 
biological activities of UroA on lipid metabolism and insulin sensitivity, we employed a 
daily intraperitoneal (i.p.) injection of UroA in a physiologically relevant concentration (20 
μg/mice). We reasoned that i.p. injection (1) bypasses the gastrointestinal tract, thereby 
avoiding redundant microbial catabolism of UroA, and (2) prompts the entry of the sub-
stance directly through the portal vein followed by hepatic first-pass metabolism before 
reaching systemic circulation (21). Here, we report that UroA injection mediates the en-
hanced insulin sensitivity against a high-fat (HF) diet. Our results support the direct bio-
logical function of UroA in modulating systemic insulin sensitivity and emphasize the 
metabolic significance of this gut-derived EA metabolite. 
 
Methods 
 
UroA preparation 
UroA was obtained as described elsewhere (22). The stock consisted of 20 mg of UroA 
diluted in 5 mL of dimethyl sulfoxide (DMSO). This stock solution was freshly diluted with 
phosphate-buffered saline (PBS) (1:20) prior to use, and the final concentration of the UroA 
injection consisted of 20 μg per mouse, with the final DMSO blood concentration adjusted 
to < 0.3%. Control mice received the same volume of DMSO. 
 
Animals 
All animal procedures were approved by the Institutional Animal Care and Use Commit-
tee at the University of Nebraska–Lincoln. C57BL/6 male mice (Jackson Laboratory, Bar 
Harbor, Maine) were fed a HF diet ad libitum. The AIN-93 M purified rodent formulation 
was modified for fat composition consisting of 45% of the kilocalories from fat. All diet 
ingredients were purchased from Dyets, Inc. (Bethlehem, Pennsylvania). Mice were in-
jected with either 100 μL vehicle (n = 8) or UroA (n = 8) daily for 12 weeks. BW change was 
monitored weekly. A glucose tolerance test (GTT) was performed on overnight-fasted mice 
by i.p. injection of 10% D-glucose (0.5 g/kg BW) (MilliporeSigma). Blood glucose levels 
were measured at 0, 30, 60, and 120 minutes post injection using a glucometer (Bayer Con-
tour; Ascensia Diabetes Care, Basel, Switzerland). Blood was collected at 30 minutes post 
glucose injection during the GTT to measure insulin levels by enzyme-linked immuno-
sorbent assay (ELISA) (Crystal Chem, Elk Grove Village, Illinois). An insulin tolerance test 
(ITT) was conducted 1 week after the GTT by injecting 1 U/kg human insulin (Novolin R; 
Novo Nordisk, Plainsboro, New Jersey). To study insulin signaling, mice (n = 4 per group) 
were fasted for 6 hours prior to i.p. injection of 1 U/kg human insulin. Liver and adipose 
tissues were collected at 15 minutes post insulin injection, and tissues were snap-frozen in 
liquid nitrogen and kept frozen until the assay. Peritoneal macrophages were collected 
from the peritoneal cavity and pooled for quantitative polymerase chain reaction (qPCR) 
analysis. 
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Cell culture 
To obtain bone marrow–derived macrophages (BMDM), primary bone marrow was iso-
lated from femurs and tibias from 5-week-old C57BL/6 mice as previously described (23). 
To investigate the role of UroA in macrophage polarization, BMDM were pretreated with 
either 30μM UroA or vehicle control (DMSO) in Opti-MEM (Gibco; Thermo Fisher Scien-
tific, Waltham, Massachusetts) for 12 hours. To induce M1 polarization, BMDM were stim-
ulated with lipopolysaccharide (LPS) (100 ng/mL) for 3 hours. To induce M2 macrophage 
polarization, medium containing interleukin (IL)-4 (100 ng/mL) and IL-13 (10 ng/mL) was 
added to the BMDM for 24 hours. The human hepatoma Huh7 cells were seeded at 2.5 × 
105 cells per well in a six-well plate. At 70% confluence, cells were pretreated with 30μM 
UroA for 12 hours. To induce lipid accumulation, 400μM bovine serum albumin (BSA)-
complex palmitic acid was added for 12 hours. BSA was used as negative control. 
 
Measurement of oxygen consumption rate 
BMDM underwent a Mito Stress Test to measure oxygen consumption rate (OCR) for basal 
and maximal respiration and ATP production using a Seahorse XFe24 extracellular flux 
analyzer (Agilent, Santa Clara, California). BMDM were cultured in a gelatin-coated Sea-
horse microplate (~12.5 × 104 cells/well). After pretreatment with 30μM UroA, BMDM were 
treated with IL-4 (100 ng/mL) and IL-13 (10 ng/mL) for M2 polarization for 24 hours. The 
cells were then treated with oligomycin (1μM) to measure ATP turnover. The maximum 
respiratory capacity was assessed by addition of carbonyl cyanide 4-trifluoromethoxy-
phenylhydrazone (FCCP) (0.3μM), a chemical uncoupler of electron transport and oxida-
tive phosphorylation. Mitochondrial respiration was blocked by antimycin A (1μM) plus 
rotenone (1μM). OCR was calculated by plotting the O2 tension of the medium in the mi-
croenvironment above the cells as a function of time (picomoles O2 per minute). The extra-
cellular acidification rate was calculated by measuring the acidity of the medium as a func-
tion of time (mpH per minute). 
 
Liver TG quantification and blood biochemical parameters 
A colorimetric TG quantification kit (Biovision, Milpitas, California) was used to quantify 
plasma and hepatic TG content according to the manufacturer’s protocol. Total and low-
density lipoprotein cholesterol (Abcam, Cambridge, UK) and nonesterified free fatty acids 
were measured using enzymatic kits (Wako Diagnostics, Richmond, Virginia). Plasma lev-
els of adiponectin levels were quantified by commercial ELISA kit (R&D Systems, Minne-
apolis, Minnesota). 
 
Hematoxylin and eosin staining and adipocyte size analysis 
During necropsy, sections of the liver and epididymal white adipose tissue (eWAT) were 
immediately fixed (10% formalin), embedded in paraffin, cut to 10-μm sections, and pro-
cessed for hematoxylin and eosin (H&E) staining. Adipocyte size was quantified using 
ImageJ and Adiposoft software (NIH, Bethesda, Maryland) (24). 
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Mitochondrial DNA quantification by qPCR 
Liver and eWAT were analyzed for their mitochondrial DNA (mtDNA)/nuclear DNA 
(nDNA) ratio. Briefly, ~50 mg of liver and eWAT was homogenized using DNAzol Reagent 
(Invitrogen, Thermo Fisher Scientific), and the supernatant was retrieved. Quantitative re-
verse transcription PCR (qRT-PCR) was performed in duplicate using mtDNA-specific pri-
mers (16S ribosomal RNA) and nuclear-specific primers (hexokinase 2). 
 
qRT-PCR 
Gene-specific primers for qRT-PCR were obtained from Integrated DNA Technologies 
(Coralville, Iowa). Total RNA was isolated using TRIzol Reagent (Invitrogen). Gene expression 
was determined by real-time qPCR (ABI 7300, Applied Biosystems, Foster City, Califor-
nia), and relative gene expression was determined based on the 2−ΔΔCT method with nor-
malization of the raw data to 18S ribosomal RNA or hypoxanthine-guanine phosphoribo-
syltransferase (Hprt). The primer sequences for qPCR are available in Supplemental Table S1. 
 
Western blot analysis 
Tissues were homogenized in radioimmunoprecipitation assay buffer containing protease 
inhibitors (MilliporeSigma, Burlington, Massachusetts) and phosphatase inhibitors (2mM 
Na3VO4, 20mM β-glycerophosphate, and 10mM NaF). Proteins were fractionated using 
10% to 12% sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE), 
transferred to polyvinylidene fluoride or polyvinylidene difluoride membranes, and incu-
bated with the relevant antibodies. Chemiluminescence solution (Western Lightning; 
PerkinElmer, Waltham, Massachusetts) was detected using a FluorChem E imaging sys-
tem (Cell Biosciences, Palo Alto, California). The sources of antibodies used in this work 
are listed in Supplemental Table S2. 
 
Statistical analysis 
Results are presented as mean ± SEM. The data were statistically analyzed by t test or one-
way analysis of variance (ANOVA) with Tukey multiple comparison tests. All analyses 
were performed with GraphPad Prism 5 (version 5.04; GraphPad Software, San Diego, 
California). 
 
Results 
 
UroA improved insulin sensitivity in mice 
To evaluate the role of UroA in modulating insulin sensitivity in vivo, mice were injected 
daily with UroA (20 μg/d) or DMSO (vehicle) for 12 weeks during HF diet feeding (Figure 
1B). Although there was no difference in BW, UroA injection significantly improved the 
plasma lipid profile by decreasing total and low-density lipoprotein cholesterol levels. 
However, UroA showed no significant impacts on high-density lipoprotein cholesterol, 
plasma TG, and nonesterified free fatty acid content (Table 1). To investigate the effects of 
UroA on insulin sensitivity, we first conducted a GTT and ITT. HF+UroA mice displayed 
faster disposal of plasma glucose compared with HF mice (Figure 1C). Despite no differ-
ences in glucose levels at 30 minutes post glucose injection, HF+UroA mice maintained 
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lower insulin levels than HF mice, confirming their augmented insulin sensitivity. Simi-
larly, HF+UroA mice were significantly more insulin sensitive compared with HF-fed mice 
during the ITT (Figure 1E). Next, we investigated the effects of UroA on insulin signaling 
in response to acute insulin challenge (1 U/kg). The phosphorylation status of the down-
stream targets of insulin (i.e., p-serine/threonine kinase 1 [Akt] and p-insulin receptor sub-
strate 1 [IRS-1]) were significantly higher in HF+UroA mice than HF control mice both in 
the liver and adipose tissue (Figure 1F). Taken together, these results demonstrate that 
UroA exerts a direct role in improving insulin sensitivity in both the liver and adipose 
tissue independently of its parental compounds. 
 
 
 
Figure 1. UroA injection increased insulin sensitivity in C57BL/6 mice against HF diet. 
(A) Production of Uro by gut microbes from EA. (B) Experimental scheme for UroA injec-
tion for 12 weeks. (C) Glucose tolerance test (GTT) and its area under the curve (AUC). 
(D) Insulin levels measured by ELISA at 30 minutes during GTT. (E) Insulin tolerance test 
and AUC. (F) Protein expression pattern for insulin signaling upon acute insulin injection 
(1 U/kg BW). All values represented as mean ± SEM (n = 8 per group). Phosphorylated 
(p)-Akt (Ser 473), p-IRS-1 (Tyr 608), and total (t)-Akt in the adipose and liver (left) from 
n = 4 per group. Relative protein intensities normalized to β-actin quantified by ImageJ 
(right). *P < 0.05 and **P < 0.01 by t test. 
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Table 1. Phenotype and blood lipid profiles 
 HF (n = 8) HF+UroA (n = 8) P value 
Phenotypes    
   BW (g) 37.7 ± 1.40 35.7 ± 1.57 0.3540 
Blood chemistry    
   Total cholesterol (mg/dL) 164.8 ± 11.00 127.8 ± 11.43* 0.0379 
   HDL (mg/dL) 129.4 ± 2.77 130.7 ± 6.10 0.8338 
   LDL (mg/dL) 11.1 ± 0.54 7.3 ± 0.41*** 0.0002 
   NEFA (mmol/L) 0.62 ± 0.05 0.55 ± 0.06 0.3982 
   Triglycerides (mmol/L) 0.99 ± 0.05 0.89 ± 0.08 0.3404 
   Adiponectin (μg/dL) 12.9 ± 0.87 18.1 ± 1.27** 0.0073 
Values are mean ± SEM. 
*P < 0.05 by t test. 
**P < 0.01 by t test. 
***P < 0.001 by t test. 
BW, body weight; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NEFA, nonesterified free 
fatty acids. 
 
UroA decreased hepatic TG accumulation and inflammation 
Previously, we demonstrated that UroA decreased TG accumulation in human hepato-
cytes (17). To determine whether UroA injection recapitulates these results in vivo, we in-
vestigated hepatic TG regulation. UroA treatment did not induce any apparent morpho-
logical changes in the liver compared with control mice (data not shown). To confirm 
whether UroA causes phase I drug metabolism, we examined transcript levels of Cyp2e1, 
a cytochrome P450 dependent oxidase responsible for the detoxification of xenobiotics. 
There were no differences in Cyp2e1 levels between treatments, suggesting that UroA in-
jection (20 μg/d) does not cause hepatic toxicity (Figure 2A). Although liver tissue weight 
was not significantly different between treatments, an analysis of hepatic TG showed a 
significant decrease in TG levels in HF+UroA mice compared with mice fed HF alone (Fig-
ure 2B). H&E staining of the liver tissue revealed that TG accumulation was significantly 
lower in HF+UroA mice than HF mice (Figure 2C). Corroborating this, liver tissue from 
HF+UroA had decreased levels of lipogenic gene and protein expression (e.g., fatty acid 
synthase [FASN], stearoyl-CoA desaturase 1 [SCD1]) but significantly increased expres-
sion of beta-oxidation genes (carnitine palmitoyltransferase 1 [Cpt1] and sirtuin 1 [Sirt1]) 
(Figure 2D–2E). Moreover, livers from HF+UroA mice had augmented expression of reac-
tive oxygen species-quenching related genes, such as superoxide dismutase 1 (Sod1) and 2 
(Sod2) (Figure 2D). Lastly, both Il1b expression (Figure 2D) and nuclear factor-κB (NFκB) 
inhibitor alpha (IκBα) degradation (Figure 2F) were significantly decreased in HF+UroA 
liver tissue, suggesting the attenuation of NFκB activation by UroA. Consistent with re-
duced hepatic steatosis, livers from HF+UroA mice had significantly reduced levels of the 
endoplasmic reticulum stress markers of phosphorylated mitogen-activated protein kinase 
8 (p-JNK), eukaryotic translation initiation factor 2A (p-EIf2α), and mitogen-activated pro-
tein kinase 1 (p-ERK) (Figure 2F). Also, UroA increased microtubule associated protein 1 
light chain 3 (LC3II) accumulation, indicating elevated autophagy in the livers of UroA-
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injected mice (Figure 2F). Notably, the mtDNA/nDNA ratio was significantly elevated in 
HF+UroA livers (P = 0.002), indicating augmented mitochondrial biogenesis (Figure 2E). 
These results were validated in human hepatoma Huh7 cells. Consistent with our previous 
study (17), treatment of Huh7 cells with 30μM UroA reduced palmitate-induced TG accu-
mulation compared with the vehicle control, as shown in oil red O staining (Figure 2G). 
Moreover, lipogenic gene expression, including sterol regulatory element binding tran-
scription factor 1 (Srebp1c), Fasn, Scd1, acetyl-CoA carboxylase (Acc), and diacylglycerol O-
acyltransferase 2 (Dgat2), was significantly decreased in UroA-treated Huh7 cells (Figure 
2H). Simultaneously, genes related to mitochondrial fatty acid oxidation (i.e., Cpt1 and 
Sirt1) were significantly increased (Figure 2H), and Il-1β was dramatically decreased in 
UroA-treated Huh7 cells (Figure 2H). Taken together, these results suggest that aug-
mented mitochondrial activity and mass contribute to the TG-lowering effects of UroA. 
 
 
 
Figure 2. UroA attenuated hepatic TG accumulation and inflammation. (A-F) C57BL/6 
mice were fed a HF diet and given a daily injection of either UroA or DMSO for 12 weeks 
(n = 8 per group). (A) Cyp2e1 transcript levels by qPCR. (B) Liver weight (grams) and 
hepatic TG content (milligrams/gram liver). (C) H&E staining of liver tissues. (D) Hepatic 
gene expression levels measured by qPCR; Fasn and Scd1 (de novo lipogenesis), Cpt1 and 
Sirt1 (beta-oxidation), Sod1 and Sod2 (reactive oxygen species quenching), and Il1b 
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(inflammation). (E) Relative mtDNA to nDNA in the liver (n = 5). (F) Protein expression 
patterns of FASN, p-eIF2α, p-ERK, IκBα, and LC3I/II by Western blot analysis. Relative 
protein intensities normalized to β-actin quantified by ImageJ (right). (G–H) Huh7 hepa-
toma cells pretreated with either 30μM UroA or DMSO followed by stimulation with pal-
mitic acid (400μM). (G) TG accumulation in Huh7 cells by oil red O staining. (H) Gene 
expression levels of Srebp1c, Fasn, Scd1, Acc, and Dgat2 (lipogenesis); Cpt1 and Sirt1 (fatty 
acid oxidation), and Il1b (inflammation) in Huh7 cells. All values represented as mean ± 
SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 by t test. 
 
UroA decreased adipocyte hypertrophy and macrophage infiltration in adipose tissue 
Our laboratory has previously demonstrated the role of UroA in reducing lipogenesis by 
using primary cultures of human adipocytes in vitro (17). In this study, we collected eWAT 
from mice to validate the physiological function of UroA in adipose tissue. UroA injection 
tended to decrease eWAT mass (Figure 3A) and noticeably reduced adipocyte size as re-
vealed by H&E staining. A quantitative analysis of adipocyte size and distribution con-
firmed our observation of reduced hypertrophy following UroA treatment (Figure 3C–3D). 
In agreement with the reduced adipose hypertrophy, FASN and ACC levels were reduced, 
while peroxisome proliferator-activated receptor gamma (PPARγ) expression was higher 
in UroA-treated mice (Figure 3E). The smaller adipocyte size induced by UroA injection 
also correlated with increased adiponectin gene (Adipoq) expression (Figure 3F) and 
plasma levels (Table 1). 
Of note, we observed increased expression of PPARγ coactivator 1 alpha (Pgc1a; also 
known as Ppargc1a) and Sirt1 mRNA in UroA-treated eWAT (Figure 3F), implicating increased 
mitochondrial biogenesis. UroA treatment increased the expression of mitochondrial-
specific proteins in eWAT, including voltage-dependent anion-selective channel protein 
(VDAC) (mitochondrial outer membrane) and pyruvate dehydrogenase (matrix) (PDH) 
(Figure 3G). This observation was further confirmed by an increased mtDNA/nDNA ratio 
in UroA-treated eWAT compared with DMSO controls (Figure 3H). Next, we examined 
whether UroA reduces macrophage infiltration into eWAT, as adipocyte hypertrophy is 
associated with inflammation (25). Both gene and protein levels of Mcp1 and F4/80 were 
reduced following UroA injection (Figure 3F–3G). In addition, expression of CD11c also 
known as integrin alpha X (ITGAX), a proinflammatory M1 macrophage marker, was also 
drastically reduced (Figure 3G). Collectively, these results not only confirm the ability of 
UroA to reduce adipocyte hypertrophy but also reveal a previously unidentified role of 
UroA in decreasing macrophage infiltration and promoting mitochondrial biogenesis in 
eWAT. 
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Figure 3. UroA decreased adipocyte hypertrophy and macrophage infiltration. eWAT 
was harvested after daily injection of either UroA or DMSO for 12 weeks (n = 8 per group). 
(A) eWAT weight (gram, n = 8). (B) H&E staining of eWAT. (C) Average adipocyte diam-
eter (micrometers) by ImageJ. (D) Adipocyte size distribution. Line of best fit is shown 
(Gaussian curve fitting). (E) Protein expression pattern of FASN, ACC, and PPARγ in eWAT. 
Relative protein intensities normalized to β-actin quantified by ImageJ (right). (F) Gene 
expression levels of Adipoq and Fasn, Pgc1a, and Sirt1, Mcp1, and F4/80 by qPCR. (G) Pro-
tein expression pattern of VDAC1 and PDH (mitochondrial proteins) and F4/80 and 
CD11c (macrophage markers) by Western blot analysis. Relative protein intensities nor-
malized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) quantified by ImageJ 
(right). (H) mtDNA to nDNA ratio in eWAT by qPCR. All values represented as mean ± SEM. 
*P < 0.05, **P < 0.01, and ***P < 0.001 by t test. 
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UroA altered M1/M2 polarization in peritoneal macrophages 
Because UroA decreases macrophage infiltration into adipose tissue, we examined the in-
flammatory status of peritoneal macrophages (Mϕ) harvested from HF and HF+UroA 
mice. We observed a remarkable decrease in proinflammatory M1 Mϕ markers, including 
Cd11c, tumor necrosis factor (Tnfα), Il6, Il1b, and Mcp1 (Figure 4A). Conversely, the resolv-
ing M2 phenotype markers chitinase-like 3 (Ch3l3; also known as Chil3) and macrophage 
galactose N-acetyl-galactosamine specific lectin 2 (Mgl2) were significantly increased in 
peritoneal Mϕ (Figure 4A). To confirm the role of UroA in M1/M2 polarization, we pre-
treated primary BMDM with UroA. Such treatment significantly decreased Il1b and Tnfα 
expression in response to LPS stimulation (Figure 4B). In agreement with our in vivo re-
sults, UroA markedly enhanced M2 Mϕ markers of arginase, liver (Arg1), Chil3, and Mgl2 
in pretreated BMDM subsequently stimulated with IL-4 and IL-13 (Figure 4C). We next 
sought to determine the mitochondrial respiration rate of M2 polarized BMDM as a meas-
ure of UroA’s impact on macrophage metabolism. OCR was higher in M2 polarized 
BMDM than nonpolarized control Mϕ. Importantly, UroA pretreatment further promoted 
OCR for both basal and ATP production (Figure 4D). In parallel to enhanced mitochondrial 
respiration, the rank order of extracellular acidification rate in BMDM was unstimulated 
Mϕ > M2 Mϕ > M2+UroA Mϕ, indicating that UroA drives decreased anaerobic respiration 
in BMDM via alterations in glycolysis (Figure 4D). Collectively, these results uncover a 
previously unappreciated role of UroA in favoring M2 polarization of macrophages, 
thereby mediating attenuated inflammation and improving insulin sensitivity. 
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Figure 4. UroA favored M2 polarization in macrophages. (A) Peritoneal macrophages 
were collected after chronic injection with UroA for 12 weeks, and (B–D) BMDM from 
naïve mice were treated with UroA (30μM). (A) Gene expression levels in macrophages 
by qPCR; Cd11c, Tnf-α, Il6, Il1b, and Mcp1 (M1 markers) and Ch3l3 and Mgl2 (M2 mark-
ers). (B) Il1b expression after LPS stimulation for 3 hours in BMDM. (C) Gene expression 
of Arg1, Ch3l3, and Mgl2 (M2 markers) in BMDM after stimulation with IL-4 plus IL-13. 
(D) Mitochondrial OCR by extracellular flux analyzer (n = 5). Basal respiration rate and 
ATP production and extracellular acidification rate. Arrows indicate the addition of the 
respiratory inhibitor oligomycin (Oligo), FCCP, and antimycin A plus rotenone (A+R). All 
values represented as mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 by t test. Treat-
ments with different letters are significantly different from one another (P < 0.05) by one-
way ANOVA. 
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Discussion 
 
Previous studies have demonstrated compelling biological activities at the cellular level of 
UroA, a first-in-class natural compound derived from EA (7); however, its systemic meta-
bolic functions remain unclear. Our current study aims to assess the independent role of 
UroA in modulating both insulin resistance and meta-inflammation in dietary challenge 
with a HF diet. We demonstrated that UroA injection through the i.p. route (1) alleviated 
HF diet–related insulin resistance (Figure 1), (2) attenuated hepatic TG accumulation and 
adipocyte hypertrophy (Figures 2 and 3), (3) reduced hepatic and adipose inflammation 
(Figures 2 and 3), and (4) conferred resistance to HF diet–mediated M1 polarization of 
macrophages (Figure 4). Our study reveals a novel mechanism by which UroA improves 
metabolic profiles via augmentation of mitochondrial activities and biogenesis in the liver 
and adipose tissue and through promoting macrophage M2 differentiation. 
In this pilot study, we administrated 20 μg of UroA via i.p. injection, which is roughly 
equivalent to 0.8 mg/kg per mouse per day of free UroA. When we calculated the human 
equivalent dose by applying the scaling factor of 12.3 (26), the estimated value was 0.065 
mg/kg per human per day. For a 60-kg adult human, roughly ~3.9 mg of free UroA or ~7.0 
mg of UroA-glucuronide should exist in circulation to predict similar biological effects 
found in HF-fed mice. Although ~7 mg of UroA-glucuronide in the bloodstream (3.6μM in 
plasma assuming 8% of blood volume in a 60-kg adult human) seems challenging, it is 
attainable in human plasma because 0.024μM to 35μM UroA-glucuronide could be found 
in human plasma after ingestion of EA-rich fruit juice (7). 
UroA metabolites in plasma undergo rapid clearance, but turnover kinetics is not well 
known. Most studies have measured the UroA plasma concentration within a maximum 
6-hour post ingestion time frame (6,27). However, this post ingestion time frame seems to 
be valid only after chronic ingestion. Recently, Istas et al. showed that UroA metabolites 
showed up in plasma in the form of glucuronide or sulfate after 24-hour intake of 200 g to 
400 g of whole red raspberry (28). Unfortunately, we failed to collect plasma and tissue 
samples in an earlier time frame. Our efforts to quantify the UroA metabolites in the 
plasma and tissue samples collected after 24 hours of UroA injection were unsuccessful 
(only trace amounts of UroA metabolites were detected in the adipose tissue). The lack of 
information regarding the concentration and molecular form of circulatory UroA is a ca-
veat in our study. Regardless, this information provides evidence for immediate biocon-
version of i.p.-administered and insoluble UroA into bioavailable UroA metabolites (pre-
sumably glucuronidation in the liver), as no detectable UroA precipitates occur in the 
plasma or accumulate in peripheral tissues. 
In term of toxicity, it is far below the no-observed-adverse-effect levels of UroA tested 
in rats for 90 days (3,451 mg/kg and 3,826 mg/kg of BW per day in male and female rats, 
respectively) (29). Consistent with this finding, we did not observe any phenotypic abnor-
malities in the livers of mice injected with UroA (data not shown), nor did we observe 
induction of phase I drug metabolism such as Cyp2e1 activation (Figure 2A). Accumulating 
evidence has supported that UroA undergoes biotransformation in the liver through phase 
II conjugation (30,31). As a result, UroA-glucuronide is formed as the principal metabolite 
found in plasma, tissues, and urine over UroA-aglycone conjugates (7). 
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Either produced by gut microbial actions or chemically synthesized, UroA exerts plei-
otropic effects in various cell types (7). Although metabolic findings do differ among studies, 
the following two underlying mechanisms are common and correlate with UroA-mediated 
health benefits: (1) activation of mitochondrial function and quality control and (2) sup-
pression of proinflammatory signaling. Here, we discussed how these two underlying 
mechanisms fit with our findings that UroA improves insulin sensitivity via regulation of 
mitochondrial activities and inflammation. 
One critical signal necessary for upregulation of mitochondrial activities is 5’-AMP-
activated protein kinase (AMPK). Upon activation by a vast range of polyphenolic com-
pounds, AMPK turns off anabolic pathways such as TG accumulation, but it turns on cat-
abolic pathways such as beta-oxidation (32). A few studies have reported that consump-
tion of EA-rich foods improves insulin sensitivity and attenuates lipid accumulation and 
inflammation through, at least in part, AMPK activation (17,33). Zhao et al. found that 
raspberries improved insulin sensitivity, lowered lipid accumulation and inflammation, 
and increased skeletal mitochondrial capacity in wild-type mice but not in AMPK-/- mice 
(33). Previously, our labs demonstrated the direct role of UroA for AMPK phosphorylation 
and beta-oxidation when primary adipocytes and Huh7 cells were treated with UroA (17). 
In our current study, we observed reduced TG accumulation and increased beta-oxidation 
in both liver and adipose tissue (Figures 2 and 3). Unexpectedly, differences in AMPK ac-
tivation were less evident (data are not shown), presumably because of the fasting status 
of the mice at the time of necropsy. Alternatively, we observed increased accumulation of 
LC3II, a sign for autophagic activation (Figure 2F), and mitochondrial biogenesis (Figure 
2E) in livers from UroA-treated mice. The autophagy activation is linked with the removal 
of damaged organelles to maintain the cellular homeostasis including mitochondria (34). In 
support of this notion, emerging evidence has suggested that UroA promotes mitophagy 
in C. elegans and rat muscle (18), as well as in UroA-treated J774.1 macrophages (35). UroA 
promotion of mitochondrial biogenesis (Figure 2E) could be expected, as tight coordina-
tion was shown between mitophagy and mitochondrial biogenesis to maintain mitochon-
drial homeostasis (36). Collectively, our results demonstrate that UroA promotes mito-
chondrial activities by maintaining healthy mitochondrial homeostasis and mitochondrial 
biogenesis. 
One unequivocal response we routinely observed upon UroA administration was the 
remarkable suppression of inflammation (13,37). In particular, we saw a significant reduc-
tion in the expression of proinflammatory markers, cytokines, and chemokines in liver, 
adipose, and macrophages of UroA-injected mice (Figures 2, 3, and 4). Because adipose 
inflammation plays a critical role in whole-body insulin resistance, UroA-induced insulin 
sensitivity (Figure 1) might result from the cumulative effects of UroA on adipose tissue 
by reducing hypertrophy (Figure 3C–3D, 3G), elevating adiponectin levels (Table 1), and 
inhibiting macrophage infiltration (Figure 3G). Importantly, our findings support a novel 
function of UroA in promoting M2 polarization. We demonstrated that UroA not only 
markedly decreased M1 polarization but also simultaneously increased M2 polarization in 
vivo (Figure 4A) and in vitro (Figure 4B–4C). Advances in immunometabolism have re-
vealed that M2 Mϕ utilizes ATP from oxidative phosphorylation, whereas M1 Mϕ favors 
ATP from substrate-level phosphorylation during glycolysis (38). Conforming to this 
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metabolic switch, UroA further increased mitochondrial oxygen consumption (Figure 4D), 
a finding supported by Ryu et al. who showed increased aerobic capacity and OCR in skel-
etal muscle following UroA treatment (18). Taken together, our results indicate that UroA 
acts on macrophages to induce M2 differentiation, thereby contributing to the reduced in-
flammation and metabolic improvements. 
The mode of action that UroA exerts for health benefits is reminiscent of resveratrol. 
Resveratrol was shown to activate SIRT1, a histone deacetylase (39). Previous studies showed 
that the parental compound of UroA, EA, modulated histone-arginine methylation (40). 
Consequently, future studies investigating whether UroA directly affects histone modifi-
cations may prove worthwhile. In addition, UroA may also exert an immediate effect on 
insulin signaling. Tang et al. found that UroA might directly target the phosphoinositide-
3-kinase (PI3K)/Akt pathway in the primary neonatal rat myocardiocytes (20), suggesting 
that multiple signaling pathways could be involved in UroAmediated improvements in 
insulin sensitivity. 
 
Conclusion 
 
We demonstrated that UroA is capable of attenuating HF diet–induced obesity and insulin 
resistance. Here, we also identified a novel immune-modulatory role of UroA in macro-
phages that favor M2 polarization. Additionally, we observed that UroA regulates signal-
ing pathways previously proposed to potentiate mitochondrial activities. Future studies 
should determine the active concentration range of UroA in the hepatic and peripheral 
tissues necessary to exert metabolic benefits. Furthermore, it should be evaluated whether 
oral consumption of UroA would be as effective as UroA injection. We believe our study 
builds on growing evidence of UroA’s ability to increase mitochondrial respiration and 
sheds new light on the dietary strategy to boost this gut metabolite to circumvent obesity-
mediated metabolic complications. 
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Table S1. Primer sequences for qPCR 
Gene Forward/Reverse Sequence (5′-3’) 
mAdiponectin Forward ACAATGGCACACCAGGCCGT Reverse TGCCAGGGGTTCCGGGGAAG 
mFas Forward GGAGGTGGTGATAGCCGGTAT   Reverse TGGGTAATCCATAGAGCCCAG   
mScd1 Forward GGGACAGATATGGTGTGAAACTATG Reverse TTACAGACACTGCCCCTCAAC 
mF4/80 Forward CTTTGGCTATGGGCTTCCAGTC Reverse GCAAGGAGGACAGAGTTTATCGTG 
mCpt1 Forward CCAGGCTACAGTGGGACATT Reverse AAGGAATGCAGGTCCACATC 
mSirt1 Forward TCGTGGAGACATTTTTAATCAGG Reverse GCTTCATGATGGCAAGTGG 
mSod1 Forward CGTACAATGGTGGTCCATGA Reverse GTTTACTGCGCAATCCCAAT 
mSod2 Forward AACTCAGGTCGCTCTTCAGC Reverse GCTTGATAGCCTCCAGCAAC 
mIl-1b Forward AAATACCTGTGGCCTTGGGC Reverse CTTGGGATCCACACTCTCCAG   
mPgc1a Forward CCCTGCCATTGTTAAGACC Reverse TGCTGCTGTTCCTGTTTTC 
  hSCD1 Forward GGGTGAGGGCTTCCACAACTA Reverse CGGCCATGCAATCAATGAA 
  hSREBP1c Forward TGC ATT TTC TAG CAC GCT TC Reverse GAT GTT CCC GGA ATA GCT GA 
  hFAS Forward GGCAAGCTGAAGGACCTGTCTA Reverse AATCTGGGTTGATGCCTCCGT 
  hACC Forward CATCAAATGCATCAGCAGAGACT Reverse CTGCGTCATATGGATGATGGAAT 
  hDGAT2 Forward TCCAGCTGGTGAAGACACAC Reverse TCACTTCTGTGGCCTCTGTG 
  hCPT1 Forward CTTTGGCCCTGTAGCAGATGA Reverse TCGTCTCTGAGCTTGAGAACTT 
  hSIRT1 Forward CGGAAACAATACCTCCACCT Reverse CACCCCAGCTCCAGTTAGAA 
  hIL-1b Forward GCCCTAAACAGATGAAGTGCTC   Reverse GAACCAGCATCTTCCTCA   
  mMcp1 Forward AGGTCCCTGTCATGCTTCTG Reverse GCTGCTGGTGATCCTCTTGT 
  mCd11c Forward CTGGATAGCCTTTCTTCTGCTG Reverse GCACACTGTGTCCGAACTC 
  mTnfa Forward GGCTGCCCCGACTACGT Reverse ACTTTCTCCTGGTATGAGATAGCAAAT 
  mIl-6 Forward CTGCAAGAGACTTCCATCCAGTT Reverse AGGGAAGGCCGTGGTTGT 
  mCh313 Forward AGAAGGGAGTTTCAAACCTGGT Reverse GTCTTGCTCATGTGTGTAAGTGA 
  mMgl2 Forward TTAGCCAATGTGCTTAGCTGG Reverse GGCCTCCAATTCTTGAAACCT 
  mArg1 Forward CTCCAAGCCAAAGTCCTTAGAG Reverse AGGAGCTGTCATTAGGGACATC 
  mHPRT Forward TTGCTCGAGATGTCATGAAGGA Reverse AGCAGGTCAGCAAAGAACTTATAGC 
  h18s Forward TCAACTTTCGATGGTAGTCGCCGT Reverse TCCTTGGATGTGGTAGCCGTTTCT 
  mCyp2e1 Forward TTCCCTAAGTATCCTCCGTGA Reverse CGTAATCGAAGCGTTTGTTG 
  m16s rRNA Forward CCGCAAGGGAAAGATGAAAGAC Reverse TCGTTTGGTTTCGGGGTTTC 
  mHexokinase 2 Forward GCCAGCCTCTCCTGATTTTAGTGT Reverse GGGAACACAAAAGACCTCTTCTGG 
m18s Qiagen cat. number QT02448075 
 
  
Table S2.  List of antibodies used in Western blotting 
Antibody name Catalog number Company Isotype Dilution 
β-actin 4967 Cell Signaling Technology Rabbit 1:1000 
p-AKT (Ser473) 4060 Cell Signaling Technology Rabbit 1:2000 
t-AKT 9272 Cell Signaling Technology Rabbit 1:1000 
p-IRS1 (Tyr608) mouse/  
(Tyr612) human 09-432 Millipore Rabbit 1:1000 
CD11c 97585 Cell Signaling Technology Rabbit 1:1000 
F4/80 70076 Cell Signaling Technology Rabbit 1:1000 
FAS 3180 Cell Signaling Technology Rabbit 1:1000 
P-JNK (Thr183/Tyr185) 4668 Cell Signaling Technology Rabbit 1:1000 
T-JNK (SAP/JNK) 9252 Cell Signaling Technology Rabbit 1:1000 
Phospho-eIF2α (Ser51) 9721 Cell Signaling Technology Rabbit 1:1000 
P-ERK (p44/42) 4695 Cell Signaling Technology Rabbit 1:1000 
IκBα 4812 Cell Signaling Technology Rabbit 1:1000 
LC3 I/II 2775 Cell Signaling Technology Rabbit 1:1000 
ACC 3676 Cell Signaling Technology Rabbit 1:1000 
PPARγ 81B8 Cell Signaling Technology Rabbit 1:1000 
VDAC1 4661 Cell Signaling Technology Rabbit 1:1000 
PDH 3205 Cell Signaling Technology Rabbit 1:1000 
GAPDH Sc-137179 Sana Cruz Biotechnology Mouse 1:500 
 
